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wards, with caring personnel (who may be staff physicians, 
physician's assistants, family nurse practitioners, or best, a 
combination) and superb nurses would be better. 
Most medical students begin their careers with interest, 
enthusiasm, and energy. It is our job as teachers and physi-
cians to make certain that these qualities are not only pre-
served but also heightened and transmitted to the care of 
patients. Each patient should legitimately feel, as should his 
or her physician, that he or she is a "great case." 
Sacramento, CA 95817 
Dr. Levinsky replies: 
FAITH FITZGERALD, M.D. 
University of California, Davis, 
Medical Center 
To the Editor: As Dr. Shurin indicates, nurse practitioners 
and physician's assistants will have increasingly important 
roles in the delivery of primary care. They will not, however, 
replace primary care physicians. My article dealt with 
means to recruit adequate numbers of such physicians. 
I agree with Dr. Fine that professional satisfaction in pri-
mary care comes from relating to people, not from treating 
"interesting" diseases. (Indeed, I used quotation marks 
around "uninteresting" in my article to separate myself 
from the implications often attached to that word in this 
context.) It takes time to talk to patients and to understand 
them as people. I believe that a restructuring of the econom-
ics of primary care is needed. Otherwise, the time allotted to 
an office visit will continue to be too short for developing and 
maintaining the personal relationship necessary for both pa-
tient and practitioner. 
Dr. Siwek believes that altering the criteria for admission 
to medical schools will greatly affect the percentage of U.S. 
medical graduates who choose primary care. The experience 
at Jefferson Medical College is instructive in this regard. 1 
Graduates of a special program combining a selective ad-
missions policy with a special educational program are far 
more likely to practice primary care than their classmates in 
the regular program atJefferson. Over the past decade, how-
ever, the percentage of available places filled in the special 
program has decreased to 33 percent. As I stated in my 
article, I believe that we will not recruit adequate numbers 
of generalists by alterations in selection criteria and educa-
tional reform alone. 
Contrary to Dr. Kieliszek's impression, the Department 
of Medicine at Boston University, which is responsible for 
patient care both at University Hospital and Boston City 
Hospital, prides itself on training physicians for the practice 
of general internal medicine, as well as for subspecialty 
practice or an academic career. In fact, our primary care 
residency is the largest federally funded primary care resi-
dency program in the United States and one of the most 
successful. 2 His impression that Boston University considers 
training at Boston City Hospital somehow uninteresting is 
mistaken. The integrated Boston University medical resi-
dency includes both Boston City Hospital and University 
Hospital as major and equal partners. 
NORMAN G. LEVINSKY, M.D. 
Boston, MA 02118 Boston University Medical Center 
I. Rabinowitz HK. Recruitment, retention, and follow-up of graduates of a 
program to increase the number of family physicians in rural and underserved 
areas. N Engl J Med 1993;328:934-9. 
2. Goldenberg DL, Pozen IT, Cohen AS. The effect of a primary-care path· 
way on internal medicine residents' career plans. Ann Intern Med 1979;91: 
271-4. 
SHATTUCK LECTURE - MISCONDUCT IN 
MEDICAL RESEARCH 
To the Editor: In his Shattuck Lecture as published in the 
journal (June 3 issue),1 Congressman John Dingell says that 
the Subcommittee on Oversight and Investigations of the 
U.S. House of Representatives, which he chairs, has "looked 
only at clear-cut cases involving fabrication, falsification, or 
plagiarism." He then includes among these cases the investi-
gation by his subcommittee of a 1986 paper published in 
Cell, by Dr. Thereza Imanishi-Kari and others, including 
myself. 2 Congressman Dingell's lecture is replete with sug-
gestions that it is an established fact that fabrication was 
involved in the writing of the paper. He is incorrect, as 
shown by the published record as well as the statements of 
the U.S. Attorney for Maryland. 
It has been seven years since the paper was published, 
during which time numerous papers have supported and 
extended the original findings. 3• 10 Many outside the immu-
nologic community will be surprised to learn that the science 
in the Cell paper was essentially correct, because for the past 
three years members of the media and Congressman Dingell 
have claimed that there were serious flaws in the paper. 
Dingell's charge that the paper "relied in large part on data 
that were falsified" is not only unproved but extremely un-
likely to be true. 
In his Addendum to the lecture, Congressman Dingell 
notes that even though he sent the information he had accu-
mulated to the U.S. Attorney in Baltimore, after a yearlong 
investigation the U.S. Attorney declined to prosecute. What 
he does not say is that a central reason for the lack of pros-
ecution was the invalidation by an independent forensic in-
vestigator of the evidence suggesting that Dr. Imanishi-Kari 
had produced data fraudulently (quoted in Hilts 11). Mr. 
Albert H. Lyter found that the Secret Service analyses of her 
notes from the study were "erroneous." If the science has 
stood the test of reproducibility and the evidence of fraudu-
lent data production does not hold up, there is simply no 
case against Dr. Imanishi-Kari. 
Should there be any doubt about this interpretation, 
one need only look at the U.S. Attorney's press release 
announcing his decision. 12 He noted that his office "will 
prosecute appropriate cases" and, after emphasizing· the 
care taken in his investigation, said that "prosecuting a 
criminal case on such debatable grounds would not be in the 
interests of justice." He explicitly said that the "central· 
issue" was "the fundamental validity of her scientific work" 
and that it was an issue to be decided in the scientific com-
munity. 
I must also protest Congressman Dingell's implication 
that I was under investigation by the U.S. Attorney; I was 
told explicitly that I was not. 
Congressman Dingell introduces his rendition of the facts 
by saying that Dr. Margot O'Toole was "vilified and effec-
tively driven from her profession" because she was the whis-
tle-blower in this case. In fact, Dr. lmanishi-Kari and I have 
been careful to treat her with respect, even when we totally 
disagreed with her, because we recognized the right of one 
scientist to question the work of others. It has been docu-
mented that she was not driven from her profession but 
instead chose to leave it. 13 For an extended period she made 
no known effort to return to science, and when she applied 
for a position, she gained one at the Genetics Institute. In 
fact, it is Dr. Imanishi-Kari who has been vilified, and were 
it not for the support of Tufts University she would have 
been driven from her profession. Even today it is not clear 
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whether she will be able to continue as the important con-
tributor to modern immunology that she has been. Dr. 
Imanishi-Kari's federal grants were cut off, although no de-
termination of her guilt has been made. Recently, she has 
been allowed to reapply, but the grant she previously re-
ceived was not returned to her. To my mind, Congressman 
Dingell should be apologizing to Dr. Imanishi-Kari, the real 
victim in this case, and not repeating inaccurate information 
about Dr. O'Toole. 
Congressman Dingell holds himself up as the guardian 
of the integrity of the scientific process. If that is the role of 
his subcommittee, then I believe that the subcommittee 
should be investigating the most egregious miscarriage 
of justice in this case - the leaking of the 1992 draft re-
port by the National Institutes of Health (NIH) that 
charged Dr. Imanishi-Kari with falsification. To this day, 
that report has never been officially completed or released, 
and it contained a strong dissent by two of the five members 
of the scientific panel. The leaking of the report, which 
led to its treatment as an established fact in the media, was 
in my view an illegal act that should be explained by the 
subcommittee. 
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To the Editor: Congressman John Dingell states that the 
public deserves science of the highest quality, free of fraud, 
plagiarism, and deceit. What is at issue is whether in pursu-
ing this aim he has failed to meet his own standards. 
What his lecture lacks is an appreciation of the value of 
evidence. None of the several panels of scientists (including 
ourselves) that reviewed the original allegations found suffi-
. cient evidence to negate the conclusions of the Cell paper* or 
to demonstrate that fraud had been committed. Those al-
*Weaver D, Reis MH, Albanese C, Costantini F, Baltimore D, lmanishi-Kari 
T. Altered repertoire of endogenous immunoglobulin gene expression in trans-
genic mice containing a rearranged mu heavy chain gene. Cell 1986;45:247-59. 
legations and hypotheses were concerned with the interpre-
tation of experiments and involved issues such as whether 
valid control mice were used and whether a monoclonal 
antibody had the appropriate specificity. The issue of falsifi-
cation was raised years later, in 1988 and early 1989, after 
the Secret Service, at the request of Congressman Dingell's 
subcommittee, had begun a forensic examination of the 
original laboratory records. As we have since learned, the 
forensic evidence that was used to damn Dr. Imanishi-Kari 
and colleagues could not withstand scrutiny. The belief (the 
hope?) of a U.S. Attorney, or of Mr. Dingell, that it would 
do so does not substitute for the deed. 
Claims that senior scientists at Tufts University and the 
Massachusetts Institute of Technology had agreed that the 
paper was fundamentally flawed but should not be correct-
ed are absolutely untrue, as we have testified, along with 
Dr. Baltimore, Dr. Herman Eisen, Dr. Imanishi-Kari, and 
others. Other than Dr. O'Toole, every person with direct 
knowledge of the discussions in May and June of 1986 has 
denied that there was any understanding that the paper was 
so flawed that it deserved retraction. At a meeting two of us 
attended, Dr. Imanishi-Kari told Dr. O'Toole that she was 
free to differ in her interpretations of the data in the Cell 
paper. Dr. O'Toole replied that she was satisfied by this 
statement and offered to shake hands. By no stretch of the 
imagination can this interchange be construed as an agree-
ment to retract. 
There is no evidence that Dr. O'Toole was vilified and 
virtually driven from science. Although she has stated that 
she did not think she would be given references or hired for a 
job in science, there is no evidence in the public record that 
her job applications were refused or her requests for recom-
mendation denied. Collectively, we have received only a sin-
gle request for a recommendation, which was given, and this 
was for the job that she now has. 
In science, ideas, hypotheses, and hopes are only the be-
ginning. The proof lies in the experiments. The evidence in 
this case is not well known by the public and the findings are 
still pending, yet Congressman Dingell treats his hypothesis 
as proved. If, like him, we could all guarantee the certitude 
of our hypotheses, we would be relieved of the need to per-
form experiments. Substituting advocacy for evidence con-
fuses the practices of Salem with those of science. · 
HENRY H. WoRTis, M.D. 
BRIGITTE HUBER, PH.D. 
Boston, MA 02111 Tufts University School of Medicine 
ROBERT WOODLAND, PH.D. 
University of Massachusetts 
Worcester, MA 01655 Medical School 
To the Editor: The Journal is not the appropriate forum for a 
point-by-point rebuttal of the spurious charges against Dr. 
Gallo that Congressman Dingell repeated in his Shattuck 
Lecture. I would simply like to highlight some of the omis-
sions from the lecture. 
The lecture fails to note that in 1984 Dr. Gallo and his 
colleagues demonstrated that a new retrovirus was the cause 
of AIDS and thereby paved the way for all subsequent epi-
demiologic and research efforts and for the development of a 
blood test that has saved countless thousands of lives. The 
importance of this accomplishment is not diminished by the 
fact that the isolate used for the blood test apparently had 
been contaminated accidentally by a sample sent to Dr. 
Gallo's laboratory from the Institut Pasteur. Contamination 
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by the French isolate occurred in laboratories throughout 
the world, most notably the Institut Pasteur itself. Scientists 
understand that accidental contaminations are inevitable in 
virology; they are neither sinister nor suspicious. Further-
more, Dr. Gallo's laboratory had another isolate that could 
have been used for the blood test, an isolate now widely used 
for research purposes, as well as several other isolates. 
What is most lacking in the Shattuck Lecture is any sense 
of perspective. Certainly, scientific misconduct is deplorable 
and should be combated. But we must take care that the 
cure does not become worse than the disease. If, as has 
happened in Dr. Gallo's case, the crusade against scientific 
misconduct becomes an excuse for the endless rehashing of 
unfounded charges, society will be the loser. 
Dr. Gallo's own perspective is honed by the knowledge 
that AIDS and cancer now threaten to kill hundreds of mil-
lions of people. The controversies of the past seem trivial as 
compared with that reality, and efforts to rekindle them in 
the name of uncovering scientific misconduct serve only to 
retard scientific progress. The scientific community, fortu-
nately, has its priorities in order; French researchers, for 
example, are cooperating with Dr. Gallo's laboratory on a 
range of important projects. It is past time for other commu-
nities to reevaluate their priorities. 
Washington, DC 20004 
j OSEPH N. ONEK 
Counsel for Dr. Robert Gallo 
Crowell & Moring 
Editor's note: Because Dr. Gallo's appeal of the Office of 
Research Integrity report is pending, he requested that his 
counsel respond to Mr. Dingell's Shattuck Lecture. 
To the Editor: l t would be preferable for Congressman 
Dingell to defend the work of his subcommittee without 
voicing his opinion on the details of ongoing investigations. 
By discussing the specifics of the ongoing cases involving Dr. 
Baltimore and Dr. Gallo, he denies the accused the right to 
respond, question, or cross-examine their accusers. The con-
gressman holds all the cards and is not accountable to any 
known rule book. How does one answer public accusations 
by a powerful congressman who controls the very committee 
managing the investigation? 
Dingell's first accusation against Gallo amounts to little 
more than guilt by association. Two people in Gallo's labo-
ratory, among the hundreds who worked there over a 25-
year period, were convicted of governmental "crimes." In 
finding Gallo at fault, Dingell ignores the fact that the dis-
covery of these actions required subpoena power and the 
ability to examine private bank accounts - powers not af-
forded an NIH laboratory chief Describing the affair involv-
ing Dr. Daniel Zagury, he says that Gallo himself "failed to 
report [two) deaths." Gallo was only one author in this 
multi-institutional study in the Lancet, serving primarily as a 
source of supply- he was not a principal author or investi-
gator who would be expected to know clinical details that 
changed between the date of submission and the publication 
date. Dingell also fails to mention that Zagury was exonerat-
ed of all allegations by French authorities. 
As for the AIDS blood test, Dingell's suspicions defy logic. 
If Gallo had something to hide, why would he himself first 
publish the sequence of his "IIIB" strain (one of the isolates 
referenced in the pivotal 1984 papers and the blood-test 
patent)? Were he guilty of deliberate misappropriation, his 
interests would have been better served by doing the oppo-
site. Sequencing revealed a difference of 1.3 percent in the 
genome between the French and the U.S. strains, leading 
him to suspect nothing unusual since this was typical of the 
differences between the isolates of the only other human 
retroviruses known at the time. Only in later years was 
wider mutation shown to be a defining characteristic of the 
human immunodeficiency virus. Hindsight also shows that 
neither Gallo's "IIIB" nor the original French "BRU" 
strain used for comparison was what either laboratory 
thought it was; instead, both were contaminants of the later, 
more aggressive French strain, "LAI," which contaminated 
several other laboratories around the world. By what fair 
rules of science, law, or logic should we conclude that this 
evidence suggests wrongdoing on Gallo's part? 
Dingell has at most uncovered two instances of ambigu-
ity in the Gallo affair, not a smoking gun. The implied pat-
tern of wrongdoing seems little more than a consequence of 
an intensive, years-long fishing expedition, a process that 
would no doubt find a string of small sins in anyone's life. 
What other scientists, politicians, or reporters could stand 
up to such scrutiny? Are not Gallo and Baltimore, with their 
undeniable contributions to humanity, entitled to the same 
presumption of innocence that is offered even the most vi-
cious criminals? Instead, they have been speculatively tried 
and convicted in everything but the legal forums, without 
once being afforded the normal constitutional protections. 
Should this be the price of working in science? 
Most people with AIDS are less concerned with congres-
sional self-justification than they are with finding a cure. To 
whom is Dingell accountable for diverting two of our most 
productive scientists from that goal? 
San Francisco, CA 94103 
MARTIN DELANEY 
Project Inform 
Editor's note: Congressman Dingell will be given an oppor-
tunity to respond to these letters and to Dr. Healy's Sound-
ing Board essay (in this issue of the journal) in a subsequent 
issue. 
2-CHLORODEOXYADENOSINE TO TREAT 
REFRACTORY HISTIOCYTOSIS X 
To the Editor: Treatment of histiocytosis X is palliative at 
best. It includes corticosteroids, alkylating agents, antime-
tabolites, vinca alkaloids, and irradiation. 1 Since 2-chlorode-
oxyadenosine, a purine substrate analogue active against 
lymphoid cancers,2 is toxic to monocytes in vitro,3 and since· 
tissue histiocytes are derived from circulating monocytes as 
they move from the intravascular space to soft tissues, we 
administered 2-chlorodeoxyadenosine to a patient with his-
tiocytosis X. 
A 33-year-old woman had presented at the age of 15 years 
with polyuria and polydipsia due to diabetes insipidus. Two 
years later vesiculopustular lesions developed on her gin-
giva, scalp, and vagina that were histologically consistent 
with a diagnosis ofhistiocytosis X. High-dose steroid thera-
py was administered, with improvement. The cutaneous le-
sions were treated with vinblastine; they responded at first 
but later became refractory. Oral etoposide, vincristine, 
cyclophosphamide, and methotrexate were administered, 
without benefit. 
Before treatment with 2-chlorodeoxyadenosine, the pa-
tient had numerous vesiculopustular lesions of 3 to 4 mm 
and shallow ulcers of her scalp, oral mucosa, vagina, and 
external auditory canals. Liver function was normal, the 
white-cell count was 5500 per cubic millimeter with a nor-
mal differential count, the hemoglobin concentration was 
